Biogen Inc at JPMorgan Healthcare Conference Transcript
All right. Good afternoon, everyone. My name is Cory Kasimov. I'm the senior large cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, Biogen. Obviously, looking at a very important 2020 and here to tell us about it is the company's CEO, Michel Vounatsos. And please note that following Michel's presentation is a breakout just down the hall in the [Georgian] room.
With that, I'll turn it over to Michel.
Thank you so much. Good afternoon, everyone. I hope you're doing well. It's a pleasure being here and having the opportunity to give you an update on our progress at Biogen on the way to build a multifranchise portfolio focusing on neuroscience and the huge opportunity it offers.
I fundamentally believe that Biogen is facing a clear inflection points with many near-term opportunities obviously in the field of Alzheimer's disease with a decision to go to file, but
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
